BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Chinese Patent Office
Julphar
Healthtrust
Fuji
Colorcon
Harvard Business School
Deloitte
Cipla

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,169,084

« Back to Dashboard

Summary for Patent: 6,169,084
Title: 2-methyl-thieno-benzodiazepine formulation
Abstract:The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
Inventor(s): Bunnell; Charles Arthur (Lafayette, IN), Ferguson; Thomas Harry (Greenfield, IN), Hendriksen; Barry Arnold (Guildford, GB), Sanchez-Felix; Manuel Vicente (Grayshott, GB), Tupper; David Edward (Reading, GB)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/163,769
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,169,084

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y Y A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS. ➤ Subscribe
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y Y A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS. ➤ Subscribe
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,169,084

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,617,321 2-methyl-thieno-benzodiazepine formulation ➤ Subscribe
7,303,764 2-methyl-thieno-benzodiazepine formulation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,169,084

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 018171 ➤ Subscribe
Austria 267602 ➤ Subscribe
Austria 359793 ➤ Subscribe
Australia 3362799 ➤ Subscribe
Australia 752552 ➤ Subscribe
Australia 759751 ➤ Subscribe
Australia 9591498 ➤ Subscribe
Brazil 9813228 ➤ Subscribe
Brazil 9914156 ➤ Subscribe
Canada 2304568 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Fish and Richardson
Merck
Baxter
McKesson
McKinsey
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot